Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Eribulin + M7824 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Eribulin | Halaven | Antimicrotubule Agent 12 | ||
M7824 | Bintrafusp alfa|MSB0011359C | Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68 TGFBR2 Antibody 2 | Bintrafusp alfa (M7824) is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03579472 | Phase I | Eribulin + M7824 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |